Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma |
| |
Authors: | Hee Chul Nam Bohyun Jang Myeong Jun Song |
| |
Institution: | Hee Chul Nam, Bohyun Jang, Myeong Jun Song, Department of Internal Medicine, College of Medicine, the Catholic University of Korea, Seoul 06591, South KoreaMyeong Jun Song, Division of Hepatology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon 34943, South Korea |
| |
Abstract: | Transarterial chemoembolization (TACE) is a widely used standard treatment for patients with hepatocellular carcinoma (HCC) who are not suitable candidates for curative treatments. The rationale for TACE is that intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, results in a strong cytotoxic effect as well as ischemia (conventional TACE). Recently, drug-eluting beads (DC Beads®) have been developed for transcatheter treatment of HCC to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor. DC Beads® can actively sequester doxorubicin hydrochloride from solution and release it in a controlled sustained fashion. Treatment with DC Beads® substantially reduced the amount of chemotherapeutic agent that reached the systemic circulation compared with conventional, lipiodol-based regimens, significantly reducing drug-related adverse events. In this article, we describe the treatment response, survival, and safety of TACE used with drug-eluting beads for the treatment of HCC and discuss future therapeutic possibilities. |
| |
Keywords: | Hepatocellular carcinoma Transarterial chemoembolization Conventional TACE Drug-eluting beads Treatment response |
本文献已被 CNKI 等数据库收录! |
| 点击此处可从《世界胃肠病学杂志(英文版)》浏览原始摘要信息 |
|